SEC Filing Summary: PerkinElmer, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by PerkinElmer, Inc. on August 11, 2021. The filing details the entry into a material definitive agreement to secure financing for the proposed acquisition of BioLegend, Inc. The company is incorporated in Massachusetts and trades on the New York Stock Exchange under the symbol PKI.
Key Financial Metrics and Debt Structure
The filing does not provide revenue, profit, cash flow, or margin data. The primary financial disclosure concerns a new debt facility:
- New Credit Facility: A $500 million unsecured delayed draw term loan credit facility.
- Lenders: Bank of America, N.A. (Administrative Agent) and other lenders.
- Interest Terms: Interest is payable quarterly at the base rate or eurocurrency rate plus a spread based on PerkinElmer's credit rating.
- Maturity: Loans mature on the third anniversary of the funding date.
- Bridge Facility Adjustment: Commitments under a separate 364-day senior unsecured bridge term loan facility (originally dated July 25, 2021) were reduced by $500 million concurrently with this agreement.
Material Changes and Use of Proceeds
The material change is the establishment of the $500 million credit facility to replace or supplement prior bridge financing arrangements. Proceeds from this facility are designated for:
- Funding, in part, the acquisition of BioLegend, Inc.
- Refinancing certain indebtedness of BioLegend.
- Paying fees and expenses related to the acquisition and its financing.
Covenants, Risks, and Conditions
The Credit Agreement includes customary affirmative and negative covenants, such as limitations on liens, subsidiary indebtedness, and mergers/acquisitions. Specific financial covenants include:
- Investment Grade: A debt-to-capitalization ratio covenant applies while PerkinElmer's debt is rated Investment Grade.
- Non-Investment Grade: If the rating falls below Investment Grade, the covenant is replaced by leverage ratio and interest coverage ratio covenants.
- Conditions Precedent: Borrowing is conditioned on the closing of the BioLegend acquisition and the accuracy of specified representations and warranties.
- Expiration: The facility is available until the earlier of the acquisition consummation or five business days after October 25, 2021 (potentially extendable to January 31, 2022).
Key Facts for Investor Verification
- Verify the status of the BioLegend, Inc. acquisition and whether the closing date aligns with the credit facility's availability window.
- Confirm PerkinElmer's current credit rating to determine which financial covenants (debt-to-capitalization vs. leverage/interest coverage) are currently active.
- Review the full text of the Term Loan Credit Agreement (Exhibit 99.1) for specific definitions of "Investment Grade" and detailed covenant thresholds.
- Monitor the reduction of the Goldman Sachs bridge facility to ensure no overlapping financing costs or commitments remain.